The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Update on the Treatment of Tuberculosis and Latent Tuberculosis Infection
Abstract
Tuberculosis (TB) has emerged as a global public health epidemic. Despite decreasing numbers of cases in the United States since 1992, TB remains a serious public health problem among certain patient populations and is highly prevalent in many urban areas. The responsibility for prescribing an appropriate drug regimen and ensuring that treatment is completed is assigned to the public health program or the clinician not to the patient. The initial prescribed regimen for the treatment of TB usually consists of 4 drugs: isoniazid, rifampin, pyrazinamide, and ethambutol. The minimum length for the treatment of drug-susceptible TB with a rifampin-based regimen is 6 to 9 months. Providing medications directly to the patient and watching him/her swallow the anti-TB drugs, which is termed directly observed therapy, is recommended for all patients diagnosed with TB and can help ensure higher completion rates, prevent the emergence of drug resistant TB, and enhance TB control. There has been renewed interest in the treatment of those with latent TB infection as a TB-control strategy in the United States for eliminating the large reservoir of individuals at risk for progression to TB. The 2 broad categories of persons who should be tested for latent TB infection are those who are likely to have been recently infected (such as contacts to infectious TB cases) and persons who are at increased risk of progression to TB disease following infection with Mycobacterium tuberculosis (eg, human immunodeficiency virus infection and selected medical conditions; recent immigrants to the United States from high TB-burden countries). The preferred regimen for the treatment of latent TB infection is 9 months of isoniazid. There is now renewed interest in and great need for the development of new drugs to treat TB and latent TB infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Cited by
Pulmonary Tuberculosis: Role of Radiology in Diagnosis and Management
Nachiappan, A. C., Rahbar, K., Shi, X., Guy, E. S., Mortani Barbosa, E. J., Shroff, G. S., Ocazionez, D., Schlesinger, A. E., Katz, S. I., & Hammer, M. M. (2017) · RadioGraphics · doi:10.1148/rg.2017160032 · Cited by 362
Antituberculosis drugs and hepatotoxicity
YEW, W. W., & LEUNG, C. C. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00941.x · Cited by 256
Metadata
- Authors
- Blumberg, H. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-06-08
- Volume
- 293
- Issue
- 22
- Pages
- 2776
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2038904221
- Cited by
- 190
- References
- 1
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update on the Treatment of Tuberculosis and Latent Tuberculosis Infection. https://app.cochat.ai/papers/10.1001/jama.293.22.2776
- The paper
- Blumberg, H. M. (2005). Update on the Treatment of Tuberculosis and Latent Tuberculosis Infection. JAMA. https://doi.org/10.1001/jama.293.22.2776
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.